Evaluation of Atherectomy in the Management of Occlusive Lesions of the Common Femoral Arteries

NCT ID: NCT07142330

Last Updated: 2025-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Thromboendarterectomy is the standard technique for the treatment of symptomatic occlusive lesions of the common femoral artery. It consists of surgically controlling the artery and interrupting circulation, opening the vessel and removing the atherosclerotic plaque. However, this technique is associated with healing difficulties, postoperative infections, and debilitating incisional pain. The rise of endovascular therapies, particularly at the coronary level, has led to the emergence of new deocclusion techniques, including rotational atherectomy. This technique relies on the use of an intravascular catheter that reams out the atherosclerotic plaque while re-aspirating the resulting debris. A few studies have examined the use of rotational atherectomy for occlusive lesions of the common femoral arteries, but have not evaluated its results compared to the standard treatment. The aim of this multicenter cohort is to describe the efficacy and safety of rotational atherectomy and the standard treatment, thromboendarterectomy, in symptomatic occlusive lesions affecting the common femoral artery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femoral Artery Occlusion Atheromatous Plaques

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with scheduled atherectomy

Atherectomy

Intervention Type PROCEDURE

Two different techniques : rotational atherectomy or thromboendarterectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atherectomy

Two different techniques : rotational atherectomy or thromboendarterectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient over 18 years of age
* Non-emergency
* Claudicating patient with significant de novo calcified stenosis affecting the common femoral artery, technically eligible for revascularization by thromboendarterectomy or rotational atherectomy
* Surgery planned with either technique
* Patient's consent to participate in the study must be obtained,

Exclusion Criteria

* Patient contraindicated for either technique (for surgical or anesthesiological reasons)
* Patient with asymptomatic lesions of the common femoral artery
* Patient with a history of surgery or angioplasty/stenting of the femoral stump
* Patient with occlusion of the ipsilateral common femoral artery or external iliac artery
* Patient with an indication for additional aortofemoral, iliofemoral, femoral-popliteal, or hamstring bypass
* Patient with severe trophic disorders for which a major amputation is considered immediately in addition to revascularization
* Patient objecting to the use of their data
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ramsay Générale de Santé

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Privé de Villeneuve d'Ascq,

Villeneuve-d'Ascq, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Adrien HERTAULT, Dr

Role: CONTACT

0033620055568

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Adrien HERTAULT, Dr

Role: primary

+33620055568

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAFAL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.